MedPath

Fresenius Kabi Deutschland Gmbh

🇸🇪Sweden
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.fresenius-kabi.com

Clinical Trials

43

Active:34
Completed:6

Trial Phases

3 Phases

Phase 1:23
Phase 3:1
Not Applicable:6

Drug Approvals

143

NMPA:71
CIMA_AEMPS:39
SFDA:16
+2 more agencies

Drug Approvals

Linezolid and Glucose Injection

Product Name
利奈唑胺葡萄糖注射液
Approval Number
国药准字HJ20240040
Approval Date
Jun 11, 2024
NMPA

Propofol Injectable Emulsion

Product Name
静安
Approval Number
国药准字HJ20170313
Approval Date
Nov 9, 2021
NMPA

Propofol Injectable Emulsion

Product Name
静安
Approval Number
国药准字HJ20170312
Approval Date
Nov 9, 2021
NMPA

Propofol Injectable Emulsion

Product Name
静安
Approval Number
国药准字HJ20170306
Approval Date
Nov 4, 2021
NMPA

Propofol Injectable Emulsion

Product Name
静安
Approval Number
国药准字HJ20170310
Approval Date
Nov 4, 2021
NMPA

Propofol Injectable Emulsion

Product Name
静安
Approval Number
国药准字HJ20170311
Approval Date
Nov 4, 2021
NMPA

Propofol Injectable Emulsion

Product Name
静安
Approval Number
国药准字HJ20170305
Approval Date
Nov 4, 2021
NMPA

Multi-trace Elements Injection (III)

Product Name
多种微量元素注射液(Ⅲ)
Approval Number
国药准字HJ20210060
Approval Date
Jul 20, 2021
NMPA

Propofol Medium and Long Chain Fat Emulsion Injection

Product Name
丙泊酚中/长链脂肪乳注射液
Approval Number
国药准字HJ20150657
Approval Date
Aug 21, 2020
NMPA

Propofol Medium and Long Chain Fat Emulsion Injection

Product Name
丙泊酚中/长链脂肪乳注射液
Approval Number
国药准字HJ20150659
Approval Date
Aug 17, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials

Phase 1
23 (76.7%)
Not Applicable
6 (20.0%)
Phase 3
1 (3.3%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.